Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 46,600 shares of the stock in a transaction on Tuesday, August 1st. The stock was acquired at an average cost of $6.25 per share, with a total value of $291,250.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $19,180,943.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Wednesday, August 2nd, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.15 per share, with a total value of $153,750.00.
- On Friday, July 28th, Phillip Md Et Al Frost purchased 35,100 shares of Opko Health stock. The stock was acquired at an average cost of $6.30 per share, with a total value of $221,130.00.
- On Thursday, July 27th, Phillip Md Et Al Frost purchased 23,600 shares of Opko Health stock. The stock was acquired at an average cost of $6.34 per share, with a total value of $149,624.00.
- On Wednesday, July 26th, Phillip Md Et Al Frost purchased 36,200 shares of Opko Health stock. The stock was acquired at an average cost of $6.39 per share, with a total value of $231,318.00.
- On Tuesday, July 25th, Phillip Md Et Al Frost purchased 39,800 shares of Opko Health stock. The stock was acquired at an average cost of $6.41 per share, with a total value of $255,118.00.
- On Monday, July 24th, Phillip Md Et Al Frost purchased 45,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.42 per share, with a total value of $288,900.00.
- On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The stock was acquired at an average cost of $6.46 per share, with a total value of $34,884.00.
- On Monday, July 17th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The stock was purchased at an average price of $6.04 per share, with a total value of $10,872.00.
- On Friday, July 14th, Phillip Md Et Al Frost acquired 12,600 shares of Opko Health stock. The stock was purchased at an average price of $6.16 per share, with a total value of $77,616.00.
- On Wednesday, July 12th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was purchased at an average price of $6.12 per share, with a total value of $22,032.00.
Opko Health, Inc. (NASDAQ:OPK) opened at 6.15 on Friday. The stock’s market capitalization is $3.44 billion. The company’s 50-day moving average price is $6.48 and its 200 day moving average price is $7.40. Opko Health, Inc. has a 12 month low of $5.99 and a 12 month high of $12.15.
Opko Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.02. The firm had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the company earned ($0.02) earnings per share. On average, analysts forecast that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock worth $181,163,000 after buying an additional 22,449,752 shares during the last quarter. State Street Corp boosted its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after buying an additional 3,138,685 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management boosted its stake in Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock worth $40,489,000 after buying an additional 1,944,549 shares during the last quarter. Vanguard Group Inc. boosted its stake in Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock worth $210,576,000 after buying an additional 1,112,843 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in Opko Health during the first quarter worth $4,450,000. 23.65% of the stock is owned by institutional investors.
Several brokerages have recently issued reports on OPK. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Jefferies Group LLC restated a “hold” rating and issued a $8.00 price objective on shares of Opko Health in a research note on Thursday, July 27th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research note on Friday, July 21st. Barrington Research raised their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a research note on Friday, June 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $14.72.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
